Allied Market Research
Loading...
Cart
0
New
New Allied Market Research

Vaccine Market By Technology (Conjugate Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, and Other Vaccines), Indication (Pneumococcal Disease, Influenza, Human Papilloma Virus, Meningococcal Disease, Rotavirus, Varicella, Diphtheria, Pertussis, & Tetanus {DPT}, Polio, Hepatitis, Measles, Mumps, & Rubella {MMR}, and Other Indications), and End Use (Pediatric Vaccines, Adult Vaccines, and Traveler Vaccines): Global Opportunity Analysis and Industry Forecast, 2020–2027

A00168
Pages: 294
Nov 2020 | 15174 Views
 
Author(s) : Sayali Shinde & Apoorva Srivastava , Onkar Sumant
Tables: 119
Charts: 57
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Vaccine Market

Request Now !

Vaccine Market Overview:

The global vaccine market size accounted for $32,462 million in 2019, and is expected to reach $54,150 million by 2027, registering a CAGR of 6.6% from 2020 to 2027.

Vaccines, also known as immunizations, inject a weakened form of a disease into a person so the body begins producing antibodies or immunity against the disease. Effective immunization has eradicated a number of diseases, like polio and smallpox, with high death rates. Vaccinations play a crucial role to maintain sustainable health of people across different countries; hence, they are employed in various regional disease-prevention strategies. The demand for vaccinations has increased over the past few years, owing to increase in incidence of both viral and bacterial infectious diseases. Vaccinations are essentially administered to people of different age groups, which strengthen their immune system throughout lifetime and offers protection against different types of infectious diseases.

vaccine-Market-2020-2027

Get more information on this report : Request Sample Pages

 

Due to the COVID-19 pandemic, majority of healthcare, pharmaceutical and biotechnology organizations have concentrated on diagnostics kits, safety wearables and treatment vaccines and medication against Novel coronavirus. Most of the leading companies are focusing on finding a breakthrough vaccine against Novel coronavirus. In addition, the medical professionals are engaged in providing COVID-19 related services. As a result, other healthcare segments have to face negligence. Moreover, pharmaceutical companies are prioritizing research and development of COVID-19 related diagnostics, treatments, health technologies and vaccines, as well as looking at the potential of existing treatments. All these factors are anticipated to impact the global vaccine market as well in the future.

Increase in investment toward development of new vaccines is expected to drive the global vaccines market in the coming years. For instance, researchers at Scripps Research Florida has been successful in developing a non-traditional vaccine to defeat SIVmac239 viral strain nicknamed as the “death star.” The non-traditional vaccine developed by the researchers provides durable protection to uninfected individuals from multiple forms of HIV stimulating the demand for the vaccine. In addition, rise in incidence of various infectious diseases and growth in awareness regarding early disease diagnosis and prevention drive the demand for protective vaccines; thereby, boosting the market growth.

Several efforts undertaken by organizations, including the UNICEF has increased the vaccine adoption over the years. Pan American Health Organization (PAHO) revolving fund and UNICEF supply division’s influence allows vaccines procurement at lower prices for various countries. Annually, PAHO and UNICEF procures vaccines for nearly 40 states and around 100 countries, respectively; thereby, positively impacting the adoption rate.

Immunization helps in preventing nearly 2-3 million deaths resulting from various diseases, including influenza, tetanus, diphtheria, measles, pertussis, and others. Furthermore, as per the WHO, more than 1.5 million deaths can be prevented, owing to improvement in global vaccination coverage. In 2018, around 116.3 million children under the age of 1 year received three doses of diphtheria-tetanus-pertussis (DTP3) vaccine globally. With increase in administration of vaccines, the vaccines business will expand significantly over the upcoming years.

Vaccine Market
By Technology type

Your browser does not support the canvas element.

Recombinant Vaccines & Conjugate Vaccines is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

Limited coverage for vaccination coupled with prohibitive cost related to transportation and storage of vaccines will negatively impact the industry expansion to certain extent in the near future. Moreover, stringent government regulations for product approval will prolong the process of new product introduction in the market; thereby, restraining the vaccine market growth.

Vaccine Market Segmentation

The global vaccine market is segmented into technology, indication, end user, and region. Depending on technology, the market is classified into recombinant & conjugate vaccines, live attenuated vaccines, inactivated vaccines, toxoid vaccines, and others. By indication, the market is classified into pneumococcal disease, influenza, human papilloma virus, meningococcal disease, rotavirus, varicella; diphtheria, pertussis, & tetanus (DPT), polio, hepatitis; measles, mumps, & rubella (MMR), and other indications. According to end user, the market is segmented into pediatric, adults, and travelers. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, the UK, France, Spain, Italy, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Vaccine Market
By Indication

Your browser does not support the canvas element.

Human Papilloma Virus is projected as higest CAGR segment.

Get more information on this report : Request Sample Pages

Segment review

The global vaccine market is segmented into technology, indication, end user, and region. Depending on technology, the market is classified into recombinant & conjugate vaccines, live attenuated vaccines, inactivated vaccines, toxoid vaccines, and others. By indication, the market is classified into pneumococcal disease, Influenza, human papilloma virus, meningococcal disease, rotavirus, varicella, diphtheria, pertussis & tetanus (DPT), polio, hepatitis; measles, mumps, & rubella (MMR), and other indications. On the basis of technology, the conjugate vaccine segment dominates the global market and is anticipated to continue this trend throughout the forecast period, owing to increase in government support and rise in company investments in conjugate vaccine development. In addition, by indication, the pneumococcal disease segment dominates the global market. The key factors that drive the market growth include increase in number of infectious disease and immunization programs surge in demand for vaccine products.

Based on end user, the market is divided into pediatric, adults, and travelers. Currently, the pediatric segment accounted for the majority of the vaccine market share, owing to the high demand for vaccines in infants, such as BCG vaccines, MMR vaccines, and DPT vaccines, and is expected to continue this trend during the forecast period. The traveler vaccine segment is anticipated to grow at a significant rate in the near future, owing to its crucial role in eliminating the risk of exposure to different diseases associated with people traveling to various regions. Moreover, rise in awareness of immunization about vaccination boosts the growth of this vaccine market.

Vaccine Market
By End user

Your browser does not support the canvas element.

Pediatric Vaccines holds a dominant position in 2019 and Traveler Vaccines is projected as higest growing segment.

Get more information on this report : Request Sample Pages

Snapshot of Asia-Pacific Vaccine market

Asia-Pacific presents lucrative opportunities for the key players operating in the vaccine market, owing to growth in awareness about vaccination and increase in immunization programs. Moreover, the market growth in this region is attributable to rise in demand for vaccine due to the rise in geriatric population, high awareness, and continuous funding from government to develop vaccines. Some of the other factors such as Asia-Pacific are densely populated, with India and China being the most populated countries. Thus, due to the presence of huge population, the increase in infectious disease cases is expected to drive the growth of the vaccine market in Asia-Pacific.

The key players operating in the vaccine market include Serum Institute of India Pvt. Ltd., Pfizer, Johnson & Johnson, AstraZenecea plc, GlaxoSmithKline plc, Sanofi Aventis, Merck & Co., Inc., Emergent BioSolutions Inc., and CSL Limited, Novavax, Inc.

Vaccine Market
By Region

2027
North America 
Europe
Asia-pacific
Lamea

Asia-Pacific region would exhibit the highest CAGR of 8.1% during 2020-2027.

Get more information on this report : Request Sample Pages

Key Benefits For Stakeholders

  • The study provides an in-depth analysis of the vaccine market size along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers vaccine market analysis from 2020 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
  • A comprehensive analysis of all the geographical regions is provided to determine the prevailing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and the global vaccine market growth.

Key Market Segments

By Technology type

  • Recombinant & Conjugate Vaccines
  • Live Attenuated Vaccines
  • Inactivated Vaccines
  • Toxoid Vaccines
  • Others

By Indication

  • Pneumococcal Disease
  • Influenza
  • Human Papilloma Virus
  • Meningococcal Disease
  • Rotavirus
  • Varicella, Measles, Mumps, & Rubella
  • Diphtheria, Pertussis, & Tetanus {DPT}
  • Polio
  • Hepatitis
  • Other Indications

By End User

  • Pediatric
  • Adults
  • Travelers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key market segments

1.2.1.List of key players profiled in the report

1.3.Research methodology

1.3.1.Primary research
1.3.2.Secondary research
1.3.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope

3.1.1.Top winning strategies, 2019

3.2.Top player positioning

3.2.1.Top investment pockets

3.3.Key forces shaping vaccine industry/market
3.4.Market dynamics

3.4.1.Drivers

3.4.1.1.Increase in prevalence of infectious diseases
3.4.1.2.Surge in immunization programs across the globe
3.4.1.3.Increase in R&D activities to develop new vaccine

3.4.2.Restraint

3.4.2.1.Longer timelines required for vaccine production
3.4.2.2.High cost associated with the development of vaccine

3.4.3.Opportunity

3.4.3.1.Growth opportunities in the emerging markets
3.4.3.2.Increase in healthcare spending

3.4.4.Impact Analysis

3.1.COVID-19 impact analysis on vaccine market

3.1.1.Overview
3.1.2.Impact analysis

CHAPTER 4:VACCINE MARKET, BY TECHNOLOGY

4.1.Overview

4.1.1.Market size and forecast

4.2.Recombinant & conjugate vaccine

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.Inactivated vaccines

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country

4.4.Live attenuated vaccines

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country

4.5.Toxoid vaccines

4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country

4.6.Other vaccines

4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast, by region
4.6.3.Market analysis, by country

CHAPTER 5:GLOBAL VACCINE MARKET, BY INDICATION

5.1.Overview

5.1.1.Market size and forecast

5.2.Pneumococcal disease

5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, by region
5.2.3.Market analysis, by country

5.3.Influenza

5.3.1.Key market trends, growth factors, and opportunities
5.3.2.`Market size and forecast, by region
5.3.3.Market analysis, by country

5.4.Human papilloma virus

5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Market size and forecast, by region
5.4.3.Market analysis, by country

5.5.Meningococcal disease

5.5.1.Key market trends, growth factors, and opportunities
5.5.2.Market size and forecast, by region
5.5.3.Market analysis, by country

5.6.Rotavirus

5.6.1.Key market trends, growth factors, and opportunities
5.6.2.Market size and forecast, by region
5.6.3.Market analysis, by country

5.7.Varicella, measles, mumps, and rubella (MMR)

5.7.1.Key market trends, growth factors, and opportunities
5.7.2.Market size and forecast, by region
5.7.3.Market analysis, by country

5.8.Diptheria, pertussis, and tetanus (DPT)

5.8.1.Key market trends, growth factors, and opportunities
5.8.2.Market size and forecast, by region
5.8.3.Market analysis, by country

5.9.Polio

5.9.1.Key market trends, growth factors, and opportunities
5.9.2.Market size and forecast, by region
5.9.3.Market analysis, by country

5.10.Hepatitis

5.10.1.Key market trends, growth factors, and opportunities
5.10.2.Market size and forecast, by region
5.10.3.Market analysis, by country

5.11.Other indications

5.11.1.Key market trends, growth factors, and opportunities
5.11.2.Market size and forecast, by region
5.11.3.Market analysis, by country

CHAPTER 6:VACCINES MARKET, BY END USER

6.1.Overview

6.1.1.Market size and forecast

6.2.Pediatric vaccines

6.2.1.Market size and forecast
6.2.2.Market analysis, by country

6.3.Adult vaccines

6.3.1.Market size and forecast
6.3.2.Market analysis, by country

6.4.Travelers vaccines

6.4.1.Market size and forecast
6.4.2.Market analysis, by country

CHAPTER 7:GLOBAL VACCINE MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by country
7.2.3.Market size and forecast, by technology
7.2.4.Market size and forecast, by indication
7.2.5.Market size and forecast, by end user

7.2.5.1.U.S. market size and forecast, by technology
7.2.5.2.Market size and forecast, by indication
7.2.5.3.Market size and forecast, by end user
7.2.5.4.Mexico market size and forecast, by technology
7.2.5.5.Mexico market size and forecast, by indication
7.2.5.6.Mexico market size and forecast, by end user
7.2.5.7.Canada market size and forecast, by technology
7.2.5.8.Canada market size and forecast, by indication
7.2.5.9.Canada market size and forecast, by end user

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country
7.3.3.Market size and forecast, by technology
7.3.4.Market size and forecast, by indication
7.3.5.Market size and forecast, by end user

7.3.5.1.Germany market size and forecast, by technology
7.3.5.2.Germany market size and forecast, by indication
7.3.5.3.Germany market size and forecast, by end user
7.3.5.4.France market size and forecast, by technology
7.3.5.5.France market size and forecast, by indication
7.3.5.6.France market size and forecast, by end user
7.3.5.7.UK market size and forecast, by technology
7.3.5.8.UK market size and forecast, by indication
7.3.5.9.UK market size and forecast, by end user
7.3.5.10.Italy market size and forecast, by technology
7.3.5.11.Italy market size and forecast, by indication
7.3.5.12.Italy market size and forecast, by end user
7.3.5.13.Spain market size and forecast, by technology
7.3.5.14.Spain market size and forecast, by indication
7.3.5.15.Spain market size and forecast, by end user
7.3.5.16.Rest of Europe market size and forecast, by technology
7.3.5.17.Rest of Europe market size and forecast, by indication
7.3.5.18.Rest of Europe market size and forecast, by end user

7.4.Asia-Pacific

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country
7.4.3.Market size and forecast, by technology
7.4.4.Market size and forecast, by indication
7.4.5.Market size and forecast, by end user

7.4.5.1.Japan market size and forecast, by technology
7.4.5.2.Japan market size and forecast, by indication
7.4.5.3.Japan market size and forecast, by end user
7.4.5.4.China market size and forecast, by technology
7.4.5.5.China market size and forecast, by indication
7.4.5.6.China market size and forecast, by end user
7.4.5.7.India market size and forecast, by technology
7.4.5.8.India market size and forecast, by indication
7.4.5.9.India market size and forecast, by end user
7.4.5.10.Australia market size and forecast, by technology
7.4.5.11.Australia market size and forecast, by indication
7.4.5.12.Australia market size and forecast, by end user
7.4.5.13.Rest of Asia-Pacific market size and forecast, by technology
7.4.5.14.Rest of Asia-Pacific market size and forecast, by indication
7.4.5.15.Rest of Asia-Pacific market size and forecast, by end user

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country
7.5.3.Market size and forecast, by technology
7.5.4.Market size and forecast, by indication
7.5.5.Market size and forecast, by end user

7.5.5.1.Brazil market size and forecast, by technology
7.5.5.2.Brazil market size and forecast, by indication
7.5.5.3.Brazil market size and forecast, by end user
7.5.5.4.Saudi Arabia market size and forecast, by technology
7.5.5.5.Saudi Arabia market size and forecast, by indication
7.5.5.6.Saudi Arabia market size and forecast, by end user
7.5.5.7.South Africa market size and forecast, by technology
7.5.5.8.South Africa market size and forecast, by indication
7.5.5.9.South Africa market size and forecast, by end user
7.5.5.10.Rest of LAMEA market size and forecast, by technology
7.5.5.11.Rest of LAMEA market size and forecast, by indication
7.5.5.12.Rest of LAMEA market size and forecast, by end user

CHAPTER 8:COMPANY PROFILES

8.1.AstraZeneca plc.

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Product portfolio
8.1.4.Business performance

8.2.CSL Limited

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance

8.3.Emergent BioSolutions Inc.

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.3.1.Key strategic moves and developments

8.4.GlaxoSmithKline plc.

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments

8.5.Johnson & Johnson

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments

8.6.MERCK & CO. INC.

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments

8.7.NOVAVAX, INC.

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance

8.8.PFIZER INC.

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments

8.9.Sanofi S.A.

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments

8.10.SERUM INSTITUTE OF INDIA PVT. LTD

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio

LIST OF TABLES

TABLE 01.GLOBAL VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 02.RECOMBINANT & CONJUGATE VACCINE MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 03.INACTIVATED VACCINE, BY REGION, 2019–2027 ($MILLION)
TABLE 04.LIVE ATTENUATED VACCINE, BY REGION, 2019–2027 ($MILLION)
TABLE 05.TOXOID VACCINE, BY REGION, 2019–2027 ($MILLION)
TABLE 06.VACCINE MARKET FOR OTHER VACCINES, BY REGION, 2019–2027 ($MILLION)
TABLE 07.GLOBAL VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 08.VACCINE MARKET FOR PNEUMOCOCCAL DISEASE, BY REGION, 2019–2027 ($MILLION)
TABLE 09.VACCINE MARKET FOR INFLUENZA, BY REGION, 2019–2027 ($MILLION)
TABLE 10.VACCINE MARKET FOR HUMAN PAPILLOMA VIRUS, BY REGION, 2019–2027 ($MILLION)
TABLE 11.VACCINE MARKET FOR MENINGOCOCCAL DISEASE, BY REGION, 2019–2027 ($MILLION)
TABLE 12.VACCINE MARKET FOR ROTAVIRUS DISEASE, BY REGION, 2019–2027 ($MILLION)
TABLE 13.VACCINE MARKET FOR VARICELLA, MEASLES, MUMPS, AND RUBELLA (MMR), BY REGION, 2019–2027 ($MILLION)
TABLE 14.VACCINE MARKET FOR DIPHTHERIA, PERTUSSIS, & TETANUS, BY REGION, 2019–2027 ($MILLION)
TABLE 15.VACCINE MARKET FOR POLIO, BY REGION, 2019–2027 ($MILLION)
TABLE 16.VACCINE MARKET FOR HEPATITIS, BY REGION, 2019–2027 ($MILLION)
TABLE 17.VACCINE MARKET FOROTHER INDICATION, BY REGION, 2019–2027 ($MILLION)
TABLE 18.GLOBAL VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 19.VACCINE MARKET FOR PEDIATRIC, BY REGION, 2019–2027 ($MILLION)
TABLE 20.VACCINE MARKET FOR ADULTS VACCINES, BY REGION, 2019–2027 ($MILLION)
TABLE 21.VACCINE MARKET FOR TRAVELERS VACCINES, BY REGION, 2019–2027 ($MILLION)
TABLE 22.VACCINE MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 23.NORTH AMERICA VACCINE MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 24.NORTH AMERICA VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 25.NORTH AMERICA VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 26.NORTH AMERICA MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 27.U.S. VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 28.U.S. VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 29.U.S. VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 30.MEXICO VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 31.MEXICO VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 32.MEXICO VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 33.CANADA VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 34.CANADA VACCINE MARKET, BY INDICATION , 2019–2027 ($MILLION)
TABLE 35.CANADA VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 36.EUROPE VACCINE MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 37.EUROPE VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 38.EUROPE VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 39.EUROPE MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 40.GERMANY VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 41.GERMANY VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 42.GERMANY VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 43.FRANCE VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 44.FRANCE VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 45.FRANCE VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 46.UK VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 47.UK VACCINE MARKET, BY INDICATION , 2019–2027 ($MILLION)
TABLE 48.UK VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 49.ITALY VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 50.ITALY VACCINE MARKET, BY INDICATION , 2019–2027 ($MILLION)
TABLE 51.ITALY VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 52.SPAIN VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 53.SPAIN VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 54.SPAIN VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 55.REST OF EUROPE VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 56.REST OF EUROPE VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 57.REST OF EUROPE VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 58.ASIA-PACIFIC VACCINE MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 59.ASIA-PACIFIC VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 60.ASIA-PACIFIC VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 61.ASIA-PACIFIC MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 62.JAPAN VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 63.JAPAN VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 64.JAPAN VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 65.CHINA VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 66.CHINA VACCINE MARKET, BY INDICATION , 2019–2027 ($MILLION)
TABLE 67.CHINA VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 68.INDIA VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 69.INDIA VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 70.INDIA VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 71.AUSTRALIA VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 72.AUSTRALIA VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 73.AUSTRALIA VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 74.REST OF ASIA-PACIFIC VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 75.REST OF ASIA-PACIFIC VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 76.REST OF ASIA-PACIFIC VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 77.LAMEA VACCINE MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 78.LAMEA VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 79.LAMEA VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 80.LAMEA MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 81.BRAZIL VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 82.BRAZIL VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 83.BRAZIL VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 84.SAUDI ARABIA VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 85.SAUDI ARABIA VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 86.SAUDI ARABIA VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 87.SOUTH AFRICA VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 88.SOUTH AFRICA VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 89.SOUTH AFRICA VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 90.REST OF LAMEA VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 91.REST OF LAMEA VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 92.REST OF LAMEA VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 93.ASTRAZENECA: COMPANY SNAPSHOT
TABLE 94.ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 95.CSL: COMPANY SNAPSHOT
TABLE 96.CSL: OPERATING SEGMENTS
TABLE 97.CSL: PRODUCT PORTFOLIO
TABLE 98.EMERGENT SOLUTIONS: COMPANY SNAPSHOT
TABLE 99.EMERGENT SOLUTIONS: OPERATING SEGMENTS
TABLE 100.EMERGENT SOLUTIONS: PRODUCT PORTFOLIO
TABLE 101.GSK: COMPANY SNAPSHOT
TABLE 102.GSK: OPERATING SEGMENTS
TABLE 103.GSK: PRODUCT PORTFOLIO
TABLE 104.J&J: COMPANY SNAPSHOT
TABLE 105.J&J: OPERATING SEGMENTS
TABLE 106.J&J: PRODUCT PORTFOLIO
TABLE 107.MERCK: COMPANY SNAPSHOT
TABLE 108.MERCK: OPERATING SEGMENTS
TABLE 109.MERCK: PRODUCT PORTFOLIO
TABLE 110.NOVAVAX: COMPANY SNAPSHOT
TABLE 111.NOVAVAX: PRODUCT PORTFOLIO:
TABLE 112.PFIZER: COMPANY SNAPSHOT
TABLE 113.PFIZER: OPERATING SEGMENTS
TABLE 114.PFIZER: PRODUCT PORTFOLIO
TABLE 115.SANOFI: COMPANY SNAPSHOT
TABLE 116.SANOFI S.A.: OPERATING SEGMENTS
TABLE 117.SANOFI S.A.: PRODUCT PORTFOLIO
TABLE 118.SERUM INSTITUTE: COMPANY SNAPSHOT
TABLE 119.SERUM INSTITUTE: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.VACCINE MARKETSEGMENTATION
FIGURE 02.TOP WINNING STRATEGIES, BY DEVELOPMENTS, 2018-2020*
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2020*
FIGURE 04.TOP WINNING STRATEGIES: COMPANY , 2018-2020
FIGURE 05.TOP PLAYER POSITIONING, 2019
FIGURE 06.TOP INVESTMENT POCKETS
FIGURE 07.MODERATE BARGAINING POWER OF SUPPLIER
FIGURE 08.MODERATEBARGAINING POWER OF BUYERS
FIGURE 09.MODERATE THREAT OF SUBSTITUTES
FIGURE 10.HIGH INTENSITY OF RIVALRY
FIGURE 11.HIGH THREAT OF NEW ENTRANT
FIGURE 12.IMPACT ANALYSIS, VACCINE MARKET
FIGURE 14.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR RECOMBINANT & CONJUGATE VACCINES, BY COUNTRY,  2019 & 2027 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR INACTIVATED VACCINE, BY COUNTRY,  2019 & 2027 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR TOXOID, BY COUNTRY,  2019 & 2027 (%)
FIGURE 20.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR OTHERS, BY COUNTRY,  2019 & 2027 (%)

FIGURE 21.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY,  2019 & 2027 (%)
FIGURE 22.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR INFLUENZA, BY COUNTRY,  2019 & 2027 (%)
FIGURE 23.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR HUMAN PAPILLOMA VIRUS, BY COUNTRY,  2019 & 2027 (%)
FIGURE 24.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY, 2019 & 2027 (%)
FIGURE 25.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR ROTAVIRUS, BY COUNTRY,  2019 & 2027 (%)
FIGURE 26.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR VARICELLA, MEASLES, MUMPS, & RUBELLA DISEASE, BY COUNTRY, 2019 & 2027 (%)
FIGURE 27.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR DIPHTHERIA, PERTUSSIS, & TETANUS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 28.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR POLIO, BY COUNTRY,  2019 & 2027 (%)
FIGURE 29.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR HEPATITIS, BY COUNTRY,  2019 & 2027 (%)
FIGURE 30.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR OTHER INDICATIONS, BY COUNTRY,  2019 & 2027 (%)
FIGURE 31.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR PEDIATRIC, BY COUNTRY,  2019 & 2027 (%)
FIGURE 32.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR ADULT, BY COUNTRY,  2019 & 2027 (%)
FIGURE 33.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR TRAVELERS, BY COUNTRY,  2019 & 2027 (%)
FIGURE 34.ASTRAZENECA: NET SALES, 2017–2019 ($MILLION)
FIGURE 35.ASTRAZENECA: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 36.CSL: NET SALES, 2017–2019 ($MILLION)
FIGURE 37.CSL REVENUE SHARE BY SEGMENTS, 2019 (%)
FIGURE 38.CSL LIMITED: REVENUE SHARE BY REGIONS, 2019 (%)
FIGURE 39.EMERGENT SOLUTIONS: NET SALES, 2017–2019 ($MILLION)
FIGURE 40.EMERGENT SOLUTIONS: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 41.EMERGENT SOLUTIONS: REVENUE SHARE BY REGION, 2019(%)
FIGURE 42.GSK: NET SALES, 2017–2019 ($MILLION)
FIGURE 43.GSK: REVENUE SHARE BY SEGMENT, 2019(%)
FIGURE 44.GSK: REVENUE SHARE BY REGION, 2019(%)
FIGURE 45.J&J: NET SALES, 2017–2019 ($MILLION)
FIGURE 46.J&J: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 47.J&J: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 48.MERCK: NET SALES, 2017–2019 ($MILLION)
FIGURE 49.MERCK: REVENUE SHARE BY SEGMENTS, 2019 (%)
FIGURE 50.MERCK: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 51.NOVAVAX: NET SALES, 2017–2019 ($MILLION)
FIGURE 52.PFIZER: NET SALES, 2017–2019 ($MILLION)
FIGURE 53.PFIZER: REVENUE SHARE BY SEGMENTS, 2019 (%)
FIGURE 54.PFIZER: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 55.SANOFI S.A.: NET SALES, 2017–2019 ($MILLION)
FIGURE 56.SANOFI: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 57.SANOFI: REVENUE SHARE BY REGION, 2019(%)

 
 

The adoption of vaccines is expected to increase due to increase in the prevalence of infectious disease and growth in demand for vaccines for preliminary screening.

Vaccines are expected to witness high adoption in the near future, owing to increase in number of immunization programs across the globe. In addition, the market is exhibiting high growth rate, owing to surge in awareness about use of the vaccine. Moreover, rise in adoption of vaccination awareness programs is another factor that fuels the growth of the market. North America and Europe are expected to offer lucrative growth opportunities to the key players. This is majorly attributed to factors such as improvement in healthcare facilities, rise in disposable income, and rapid improvement in economic conditions. However, high monetary inputs required for the production of these vaccines hinders the growth of the vaccine market. Vaccines manufacturers and distributors have focused on expanding their presence in the emerging economies to strengthen their foothold in the market.

 

 

 

 
PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, T&C*

PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. The total market value of vaccine market is $32,462.5 million in 2019.

A. The forcast period for vaccine market is 2020 to 2027

A. The market value of vaccine market in 2027 is $ 54,167.55 million.

A. The base year is 2019 in vaccine market

A. Top companies such as GlaxoSmithKline plc, Sanofi Aventis, Pfizer Inc., Merck & Co., Inc. held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in different regions.

A. In technology type segment recombinant & conjugate vaccines is the most influencing segment. Hence, these vaccines are considered to be the most efficient alternative to traditional vaccines in the prevention of various human diseases. The increasing numbers of regulatory clearances have made the highest impact on the market in recent years.

A. The major factor that fuels the growth of the global vaccine market includes increase in prevalance of infectious diseases, surge in immunization programs, and increase in R &D activities to develop new vaccine. This leads to surge in demand for vaccine devices which contribute to the growth of the market.

A. Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the emerging countries. This is due to improvement in health awareness, development in healthcare infrastructure, and increase in affordability. In addition, strategies, such as collaboration, joint venture, and agreement, adopted by the leading players in Japan are set to add boost the market growth.

A. A vaccine is a biological preparation that provides active acquired immunity and hels to protect against a particular infectious disease.

A. Vaccines are used to boost your immune system and prevent serious, life-threatening diseases.

Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Vaccine Market

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library. T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts